Indivior Pharmaceuticals, Inc. - Common Stock (INDV)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — May 9, 2026Investment Snapshot
- P/E of 24.6 — elevated valuation multiple
- Piotroski F-Score 5/9 — moderate financial health
- Strong ROE of 220.0% with 16.3% net margin
Indivior Pharmaceuticals, Inc. - Common Stock (INDV) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $4.8 billion . Key value metrics: P/E ratio 24.6, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 3 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Indivior Pharmaceuticals, Inc. - Common Stock — Fundamental Analysis Summary
Indivior Pharmaceuticals, Inc. - Common Stock (INDV) trades at a trailing P/E of 24.6x — in line with the Healthcare sector average of 25.2x.
On financial health, INDV shows a moderate Piotroski F-Score of 5/9, and strong return on equity of 220.0% (sector average: -20.6%).
StockPik's composite Value Score for INDV is 66/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
INDV reports a high gross margin of 81.6% (sector average: 40.1%) and a strong operating margin of 26.5%.
INDV shows revenue growing at 4% year-over-year, with earnings growing at 10,400%.